Has the HRT black box warning been removed?

What did FDA actually change?

FDA requested label changes on November 10, 2025, then announced the first six approved changes on February 12, 2026. The completed changes named in that announcement removed cardiovascular-disease, breast-cancer and probable-dementia statements from boxed warnings. A request to manufacturers and approval of a particular revised label are separate steps.

The initiative retained the endometrial cancer boxed warning for systemic estrogen-alone products. It also retained cardiovascular and breast-cancer risk information in the wider systemic-product labeling. Removing a statement from the box is not the same as removing every warning or contraindication.

FDA requested changes · First approved changes

Which products does FDA list as updated?

The FDA page checked on October 13 lists these six products. They include different hormones and delivery forms, so one product's revised warning should not be assigned to another.

This is the agency's published list, not our audit of every brand, generic manufacturer or package insert. An absent product name does not, by itself, establish which version a pharmacy supplies.

FDA's updated-product list and linked labels

Why might my HRT label still have a black box?

The exact product and label version can differ. These two directly checked examples show why a general removal headline is insufficient.

What risks still need discussing?

Even the revised Divigel label retains important restrictions. It lists contraindications involving breast cancer, certain clotting or arterial-thromboembolic histories, unexplained genital bleeding and liver disease, among others. The full label, not the presence or absence of one box, guides the prescribing discussion.

For someone with a uterus using systemic estrogen, the retained endometrial warning remains relevant. Divigel's label explains that adding a progestogen has been shown to reduce endometrial hyperplasia risk. That is a product-label explanation, not an instruction to choose or change a regimen yourself.

Divigel boxed warning, contraindications and warnings · HRT risks by product and evidence

Does the under-60 or within-10-years wording guarantee suitability?

No. The revised Divigel label says to consider initiation in women under 60 or within 10 years of menopause onset. It still has contraindications and warnings. Age and timing are factors in the clinical decision; they do not establish that this treatment is right for every person in that group.

Divigel, section 2.1: important use information

What should I check before my next prescription discussion?

1. Write down the exact brand or generic, manufacturer and delivery form. The estradiol brand guide helps distinguish product names.
2. Check the revision date and boxed warning in the current prescribing information. Ask the pharmacist whether it matches the supplied product.
3. Ask which warnings changed, which remain, and how the full label relates to your health history.
4. Discuss any treatment change with your prescriber. A headline alone is not a reason to stop, switch or alter a prescription.

Use the FDA list and exact label together. This checklist helps prepare questions; it does not select a medicine, route or dose.

Frequently asked questions